[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Naratriptan is combined with Antipyrine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Naratriptan.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Naratriptan.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Naratriptan is combined with Azapropazone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Naratriptan.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Naratriptan.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Naratriptan.]
[L04AX02, thalidomide, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thiethylperazine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Naratriptan.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Naratriptan is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tilidine.]
[S01ED01, timolol, Naratriptan may decrease the antihypertensive activities of Timolol.]
[M02AX02, tolazoline, Naratriptan may decrease the antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Naratriptan.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Naratriptan can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Naratriptan.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Naratriptan.]
[C03AA06, trichlormethiazide, Naratriptan may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Trifluperidol.]
[N05AA05, triflupromazine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Naratriptan.]
[C02BA01, trimethaphan, Naratriptan may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Naratriptan.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Naratriptan.]
[A03BB01, butylscopolamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Naratriptan.]
[C09CA09, azilsartan medoxomil, Naratriptan may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tubocurarine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Indacaterol.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Viloxazine.]
[C04AX07, vincamine, Naratriptan may decrease the antihypertensive activities of Vincamine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Warfarin.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Naratriptan is combined with Xenon.]
[C03BA10, xipamide, Naratriptan may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Levetiracetam.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ziprasidone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Naratriptan.]
[G04BD07, tolterodine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Naratriptan may decrease the antihypertensive activities of Atenolol.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Naratriptan is combined with Atracurium.]
[S01FA01, atropine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Naratriptan is combined with Mirabegron.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Naratriptan is combined with Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Barbital.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Naratriptan is combined with Rasagiline.]
[C08CA13, lercanidipine, Naratriptan may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Naratriptan.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[N02CC03, zolmitriptan, The risk or severity of vasospastic reactions can be increased when Naratriptan is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Naratriptan is combined with Diethyl ether.]
[C03AA01, bendroflumethiazide, Naratriptan may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pomalidomide.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Naratriptan is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Benperidol.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may increase the vasoconstricting activities of Naratriptan.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Benzocaine.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Celecoxib is combined with Naratriptan.]
[N04AC01, benztropine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Naratriptan is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Naratriptan is combined with Levomilnacipran.]
[C08EA02, bepridil, Naratriptan may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Naratriptan may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Naratriptan may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vigabatrin.]
[C01CA27, droxidopa, Naratriptan may increase the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, Naratriptan may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tasimelteon.]
[S01ED02, betaxolol, Naratriptan may decrease the antihypertensive activities of Betaxolol.]
[C02CC01, bethanidine, Naratriptan may decrease the antihypertensive activities of Bethanidine.]
[A03BA03, hyoscyamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Alfaxalone.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Olodaterol.]
[D11AA01, glycopyrronium, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Acepromazine.]
[N04AA02, biperiden, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dicoumarol.]
[N06AX11, mirtazapine, Naratriptan may increase the serotonergic activities of Mirtazapine.]
[A03AA09, difemerine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tioclomarol.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Naratriptan is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Naratriptan is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Naratriptan is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Naratriptan.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Acetophenazine.]
[B01AC27, selexipag, Naratriptan may decrease the antihypertensive activities of Selexipag.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Naratriptan is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Bromazepam.]
[N04BC01, bromocriptine, Bromocriptine may increase the vasoconstricting activities of Naratriptan.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naratriptan.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Amineptine.]
[C08CA01, amlodipine, Naratriptan may decrease the antihypertensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Naratriptan.]
[C07AA19, bupranolol, Naratriptan may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Naratriptan.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Naratriptan.]
[S01GX07, azelastine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Naratriptan is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Naratriptan can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Beclamide.]
[C09AA07, benazepril, Naratriptan may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Naratriptan.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Naratriptan.]
[N04BD03, safinamide, The metabolism of Naratriptan can be decreased when combined with Safinamide.]
[C07AB07, bisoprolol, Naratriptan may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Naratriptan.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Naratriptan.]
[N04AA11, bornaprine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Brotizolam.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Naratriptan is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Naratriptan is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Naratriptan is combined with Butriptyline.]
[N01BX04, capsaicin, The metabolism of Naratriptan can be decreased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vinylbital.]
[C09AA01, captopril, Naratriptan may decrease the antihypertensive activities of Captopril.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Naratriptan.]
[A03AA03, camylofine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Naratriptan.]
[C07AG02, carvedilol, Naratriptan may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Naratriptan.]
[C07AB08, celiprolol, Naratriptan may decrease the antihypertensive activities of Celiprolol.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Naratriptan.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Naratriptan is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Naratriptan is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Naratriptan.]
[R03BB08, revefenacin, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The therapeutic efficacy of Naratriptan can be decreased when used in combination with Gilteritinib.]
[C09AA08, cilazapril, Naratriptan may decrease the antihypertensive activities of Cilazapril.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Naratriptan.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Naratriptan is combined with Siponimod.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Naratriptan.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Naratriptan.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Cloxazolam.]
[C09CA06, candesartan, Naratriptan may decrease the antihypertensive activities of Candesartan.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Cyamemazine.]
[C03BX03, cicletanine, Naratriptan may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Naratriptan.]
[C03AA09, cyclothiazide, Naratriptan may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Yohimbine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Naratriptan.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Naratriptan.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lumateperone.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Naratriptan is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Naratriptan.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Naratriptan.]
[C01BD07, dronedarone, The risk or severity of hypertension can be increased when Naratriptan is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Naratriptan.]
[C02AA06, methoserpidine, Naratriptan may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Naratriptan is combined with Dopexamine.]
[G04BD09, trospium, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Naratriptan is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Naratriptan is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Naratriptan is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Naratriptan is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Naratriptan.]
[C08CA17, levamlodipine, Naratriptan may decrease the antihypertensive activities of Levamlodipine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Remimazolam.]
[N07XX04, sodium oxybate, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Naratriptan is combined with Oliceridine.]
[C03AA04, chlorothiazide, Naratriptan may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Naratriptan may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Naratriptan.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Naratriptan is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Naratriptan.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Naratriptan is combined with Etofenamate.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Naratriptan is combined with Naxitamab.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Naratriptan.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Naratriptan is combined with Fenbufen.]
[C01CA19, fenoldopam, Naratriptan may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Naratriptan is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Naratriptan is combined with Finasteride.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Naratriptan is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Naratriptan may decrease the antihypertensive activities of Dasiglucagon.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Gabapentin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Naratriptan is combined with Citalopram.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Naratriptan.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Naratriptan.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Naratriptan is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Naratriptan.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Naratriptan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Naratriptan.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Naratriptan.]
[N05AH02, clozapine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Naratriptan.]
[S02DA02, cocaine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Naratriptan may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Naratriptan is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Naratriptan.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Naratriptan.]
[A03AB10, hexocyclium, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Naratriptan is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Naratriptan is combined with Imidazole salicylate.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Naratriptan is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Naratriptan.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Naratriptan is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Naratriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Naratriptan is combined with Parecoxib.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Naratriptan is combined with Kebuzone.]
[C08CA09, lacidipine, Naratriptan may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Naratriptan can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Naratriptan is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Naratriptan is combined with Loxoprofen.]
[C09AA03, lisinopril, Naratriptan may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, Naratriptan may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Naratriptan is combined with Mefenorex.]
[N04AA03, methixene, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Cyclobarbital.]
[C03DA04, eplerenone, Naratriptan may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Naratriptan is combined with Melperone.]
[C03AA07, cyclopenthiazide, Naratriptan may decrease the antihypertensive activities of Cyclopenthiazide.]
[N06AX07, minaprine, The metabolism of Naratriptan can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The risk or severity of hypertension can be increased when Cyclosporine is combined with Naratriptan.]
[N06AG02, moclobemide, The metabolism of Naratriptan can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Naratriptan may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Naratriptan is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Naratriptan is combined with Morniflumate.]
[C02AC05, moxonidine, Naratriptan may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Naratriptan is combined with Etoricoxib.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Deanol.]
[C02CC04, debrisoquin, Naratriptan may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Naratriptan.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Nordazepam.]
[C07AB12, nebivolol, Naratriptan may decrease the antihypertensive activities of Nebivolol.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Niaprazine.]
[C01DX16, nicorandil, Naratriptan may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Naratriptan.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Naratriptan is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naratriptan.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Naratriptan is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Escitalopram.]
[G04BD08, solifenacin, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Naratriptan is combined with Olsalazine.]
[N06AA01, desipramine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Naratriptan.]
[C09XA02, aliskiren, Naratriptan may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Naratriptan is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Naratriptan.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Oxiracetam.]
[N04AA08, dexetimide, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Naratriptan.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Naratriptan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Naratriptan.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Naratriptan.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Naratriptan.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Phenacemide.]
[V03AH01, diazoxide, Naratriptan may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Naratriptan.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Naratriptan.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Naratriptan.]
[A03AA07, dicyclomine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Naratriptan may decrease the antihypertensive activities of Pinacidil.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pipamperone.]
[A03AB14, pipenzolate, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Pirbuterol.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Naratriptan.]
[C08CA03, isradipine, Naratriptan may decrease the antihypertensive activities of Isradipine.]
[A03AB11, poldine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Naratriptan.]
[C02DB01, dihydralazine, Naratriptan may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the vasoconstricting activities of Naratriptan.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the vasoconstricting activities of Naratriptan.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Naratriptan.]
[B01AC21, treprostinil, Naratriptan may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pramocaine.]
[C08DB01, diltiazem, Naratriptan may decrease the antihypertensive activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pridinol.]
[R06AB03, dimethindene, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Procaterol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Naratriptan.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Naratriptan is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Naratriptan is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Quazepam.]
[C09AA06, quinapril, Naratriptan may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Naratriptan.]
[C09AA05, ramipril, Naratriptan may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Remoxipride.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Reproterol.]
[C01BA03, disopyramide, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Naratriptan.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Naratriptan.]
[G04BE08, tadalafil, Naratriptan may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Naratriptan.]
[C02KX02, ambrisentan, Naratriptan may decrease the antihypertensive activities of Ambrisentan.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Naratriptan is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Salmeterol is combined with Naratriptan.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Dobutamine is combined with Naratriptan.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Naratriptan is combined with Dopamine.]
[N06AA16, dothiepin, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Naratriptan.]
[N06AA12, doxepin, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sibutramine.]
[C09AA11, spirapril, Naratriptan may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Naratriptan.]
[C07AB13, talinolol, Naratriptan may decrease the antihypertensive activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Naratriptan.]
[G04CA03, terazosin, Naratriptan may decrease the antihypertensive activities of Terazosin.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Naratriptan is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thiopropazate.]
[G04BD01, emepronium, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tianeptine.]
[C09AA02, enalapril, Naratriptan may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Naratriptan is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The metabolism of Naratriptan can be decreased when combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Naratriptan.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Naratriptan.]
[C03CA04, torsemide, Naratriptan may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Naratriptan is combined with Tramazoline.]
[C09AA10, trandolapril, Naratriptan may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Naratriptan is combined with Triclofos.]
[A03AB08, tridihexethyl, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Naratriptan.]
[N04AA12, tropatepine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Naratriptan.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Naratriptan is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Veralipride.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Naratriptan is combined with Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Naratriptan.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Naratriptan is combined with Xylometazoline.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Epinephrine is combined with Naratriptan.]
[C09AA15, zofenopril, Naratriptan may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Naratriptan is combined with Zomepirac.]
[N03AX15, zonisamide, The metabolism of Naratriptan can be decreased when combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Moricizine.]
[G02AB03, ergonovine, Ergometrine may increase the vasoconstricting activities of Naratriptan.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the vasoconstricting activities of Naratriptan.]
[N02CA02, ergotamine, Ergotamine may increase the vasoconstricting activities of Naratriptan.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Estazolam.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Naratriptan.]
[N04AA05, profenamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Naratriptan.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Naratriptan.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Naratriptan.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Naratriptan is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Naratriptan.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Naratriptan is combined with Sertindole.]
[R06AX12, terfenadine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Naratriptan is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Fluvoxamine.]
[C08CA02, felodipine, Naratriptan may decrease the antihypertensive activities of Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Naratriptan.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Naratriptan.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Salbutamol.]
[G04BD02, flavoxate, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Naratriptan is combined with Floctafenine.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Naratriptan is combined with Melitracen.]
[V03AZ01, ethanol, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Fluoxetine.]
[N05AF01, flupenthixol, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Naratriptan.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Naratriptan.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Naratriptan is combined with Fluspirilene.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Naratriptan is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Naratriptan is combined with Alcuronium.]
[G01AX06, furazolidone, The metabolism of Naratriptan can be decreased when combined with Furazolidone.]
[C03CA01, furosemide, Naratriptan may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Naratriptan is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Naratriptan is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Gallamine.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Naratriptan is combined with Bifemelane.]
[N04BC06, cabergoline, Cabergoline may increase the vasoconstricting activities of Naratriptan.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Naratriptan.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Naratriptan.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Glutethimide.]
[C05AE01, nitroglycerin, Naratriptan may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Naratriptan may decrease the antihypertensive activities of Doxazosin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may increase the vasoconstricting activities of Naratriptan.]
[C07AB09, esmolol, Naratriptan may decrease the antihypertensive activities of Esmolol.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Naratriptan is combined with Fluindione.]
[C09AA09, fosinopril, Naratriptan may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Naratriptan may decrease the antihypertensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Naratriptan.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Naratriptan is combined with Halothane.]
[N05AH04, quetiapine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Naratriptan is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Allobarbital.]
[C09CA01, losartan, Naratriptan may decrease the antihypertensive activities of Losartan.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Naratriptan.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Hexobarbital.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Naratriptan is combined with Hexoprenaline.]
[C08CA10, nilvadipine, Naratriptan may decrease the antihypertensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Naratriptan is combined with Nimesulide.]
[C09AA04, perindopril, Naratriptan may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Naratriptan may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Naratriptan may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Naratriptan may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Naratriptan is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[C02AC06, rilmenidine, Naratriptan may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Naratriptan is combined with Ibuprofen.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Naratriptan.]
[N06AA02, imipramine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Naratriptan.]
[C03BA11, indapamide, Naratriptan may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Naratriptan.]
[C02CA02, indoramin, Naratriptan may decrease the antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Naratriptan is combined with Milnacipran.]
[A03AA30, piperidolate, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Naratriptan.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ramelteon.]
[R06AE01, buclizine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Naratriptan.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Naratriptan is combined with Iprindole.]
[N06AF05, iproniazid, The metabolism of Naratriptan can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The metabolism of Naratriptan can be decreased when combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Naratriptan.]
[C09AA16, imidapril, Naratriptan may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Naratriptan.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Naratriptan.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Naratriptan.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Naratriptan is combined with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Naratriptan is combined with Isoxsuprine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Naratriptan.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ketanserin.]
[N05AH03, olanzapine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Naratriptan is combined with Ketoprofen.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Naratriptan is combined with Arbutamine.]
[N04BC09, rotigotine, Naratriptan may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Naratriptan is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Naratriptan may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Naratriptan.]
[C02AA05, deserpidine, Naratriptan may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Naratriptan is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of hypertension can be increased when Naratriptan is combined with Lidocaine.]
[N02CA07, lisuride, Lisuride may increase the vasoconstricting activities of Naratriptan.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Naratriptan.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Loxapine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Naratriptan can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Naratriptan.]
[C02BB01, mecamylamine, Naratriptan may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Naratriptan.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Naratriptan.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Medazepam.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Melatonin.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Naratriptan.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Naratriptan.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Naratriptan.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Naratriptan.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Naratriptan.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Naratriptan.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Naratriptan.]
[N06BA03, methamphetamine, The metabolism of Naratriptan can be decreased when combined with Metamfetamine.]
[A03AB07, methantheline, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Naratriptan is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Naratriptan.]
[G02CB05, metergoline, Metergoline may increase the vasoconstricting activities of Naratriptan.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Naratriptan.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Naratriptan.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Naratriptan.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Naratriptan is combined with Methoxyflurane.]
[C02AB01, methyldopa, Naratriptan may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Naratriptan may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the vasoconstricting activities of Naratriptan.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Naratriptan.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Naratriptan.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Naratriptan is combined with Methyprylon.]
[N02CA04, methysergide, Methysergide may increase the vasoconstricting activities of Naratriptan.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Naratriptan.]
[C03BA08, metolazone, Naratriptan may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Naratriptan may decrease the antihypertensive activities of Metoprolol.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Naratriptan is combined with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Naratriptan.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Naratriptan.]
[C09CA03, valsartan, Naratriptan may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[D11AX01, minoxidil, Naratriptan may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Naratriptan is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Molindone.]
[N06AA09, amitriptyline, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Naratriptan.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Naratriptan.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Amobarbital.]
[R03BB01, ipratropium bromide, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Naratriptan is combined with Fosphenytoin.]
[C07AA12, nadolol, Naratriptan may decrease the antihypertensive activities of Nadolol.]
[N04BC04, ropinirole, Naratriptan may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Naratriptan is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Naratriptan.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Naratriptan.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Naratriptan is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Naratriptan.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Naratriptan.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Naratriptan.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Naratriptan.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Naratriptan may decrease the antihypertensive activities of Telmisartan.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Nialamide.]
[C08CA04, nicardipine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the vasoconstricting activities of Naratriptan.]
[N07BA01, nicotine, The metabolism of Naratriptan can be decreased when combined with Nicotine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Naratriptan is combined with Niflumic acid.]
[C08CA06, nimodipine, Naratriptan may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Naratriptan may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Nitrazepam.]
[C08CA08, nitrendipine, Naratriptan may decrease the antihypertensive activities of Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Naratriptan is combined with Zaleplon.]
[N04BC05, pramipexole, Naratriptan may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Naratriptan may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Naratriptan.]
[C02KX01, bosentan, Naratriptan may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Naratriptan is combined with Nylidrin.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Naratriptan is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Naratriptan.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Naratriptan.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Naratriptan.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Naratriptan is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Naratriptan.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Naratriptan is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Naratriptan is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of hypertension can be increased when Naratriptan is combined with Oxytocin.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Naratriptan.]
[M03AC01, pancuronium, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The metabolism of Naratriptan can be decreased when combined with Pargyline.]
[G04BD11, fesoterodine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Naratriptan.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Naratriptan.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Perazine.]
[N04BC02, pergolide, Pergolide may increase the vasoconstricting activities of Naratriptan.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Naratriptan.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Naratriptan is combined with Phenindione.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Naratriptan may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Naratriptan is combined with Phenprocoumon.]
[A08AA01, phentermine, The metabolism of Naratriptan can be decreased when combined with Phentermine.]
[V03AB36, phentolamine, Naratriptan may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Naratriptan.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Naratriptan.]
[R01BA01, phenylpropanolamine, The metabolism of Naratriptan can be decreased when combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Naratriptan.]
[C08CX01, mibefradil, Naratriptan may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pindolol.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pipotiazine.]
[C09CA02, eprosartan, Naratriptan may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Naratriptan is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Naratriptan.]
[N02CX01, pizotyline, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[C09CA04, irbesartan, Naratriptan may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Naratriptan is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Naratriptan is combined with Alosetron.]
[C03AA05, polythiazide, Naratriptan may decrease the antihypertensive activities of Polythiazide.]
[C07AB01, practolol, Naratriptan may decrease the antihypertensive activities of Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Naratriptan is combined with Prazepam.]
[C02CA01, prazosin, Naratriptan may decrease the antihypertensive activities of Prazosin.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Naratriptan.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Naratriptan.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Naratriptan.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.]
[N04AA04, procyclidine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of hypertension can be increased when Naratriptan is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Naratriptan is combined with Propanidid.]
[A03AB05, propantheline, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Periciazine.]
[N05CM06, propiomazine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Naratriptan.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Naratriptan.]
[C07AA05, propranolol, The metabolism of Naratriptan can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Rizatriptan.]
[B01AC09, epoprostenol, Naratriptan may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Naratriptan.]
[R01BA02, pseudoephedrine, The metabolism of Naratriptan can be decreased when combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Naratriptan.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Naratriptan is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Naratriptan is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Mepyramine.]
[C01BA01, quinidine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Naratriptan.]
[C02AA01, rescinnamine, Naratriptan may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Naratriptan is combined with Reserpine.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Naratriptan is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Naratriptan.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Naratriptan is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Naratriptan.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Naratriptan.]
[S01FA02, scopolamine, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Naratriptan.]
[N04BD01, selegiline, The metabolism of Naratriptan can be decreased when combined with Selegiline.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Naratriptan.]
